Search - tctmd.com

Displaying 21 - 30 of 30

Sort: Relevancy | Date

Presentation THT 2022

EMPULSE: The Use of SGLT2 Inhibitors in Acute Decompensated Heart Failure

Presenter: Piotr Ponikowski

February 01, 2022

Presentation THT 2022

SGLT2 Inhibitors: What the Clinician Should Know

Presenter: Stefan Anker

February 01, 2022

Presentation THT 2022

Spectrum of SGLT2-Inhibitor Benefits: Clinical to Symptoms to Quality of Life

Presenter: Javed Butler

February 01, 2022

Presentation THT 2022

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Presenter: Alanna Morris

February 01, 2022

Presentation THT 2022

Should SGLT2 Inhibitors Be Started in the Hospital or in the Ambulatory Setting?

Presenter: Piotr Ponikowski

February 01, 2022

Presentation THT 2022

SGLT2 Inhibitors in HFrEF and HFpEF

Presenter: Stefan Anker

February 01, 2022

Presentation Controversies and Advances 2021

SGLT2 Inhibitors and Heart Failure

Presenter: Michelle M. Kittleson

December 03, 2021

Presentation TCT 2021

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Presenter: Connie Hess

November 06, 2021

Presentation TCT 2019

Novel Approaches in Diabetic Patients After PCI: Role of SGLT2 Inhibitors and Potent Antiplatelet Therapy (THEMIS)

Presenter: Marc Bonaca

September 26, 2019

Advertisement

EMPULSE: The Use of SGLT2 Inhibitors in Acute Decompensated Heart Failure

SGLT2 Inhibitors: What the Clinician Should Know

Spectrum of SGLT2-Inhibitor Benefits: Clinical to Symptoms to Quality of Life

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Should SGLT2 Inhibitors Be Started in the Hospital or in the Ambulatory Setting?

SGLT2 Inhibitors in HFrEF and HFpEF

SGLT2 Inhibitors and Heart Failure

Medical Therapy for PAD: PCSK9, SGLT2, Anticoagulation and Beyond

Novel Approaches in Diabetic Patients After PCI: Role of SGLT2 Inhibitors and Potent Antiplatelet Therapy (THEMIS)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content